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Effects of short-term fasting on cancer
treatment
Stefanie de Groot1, Hanno Pijl2, Jacobus J. M. van der Hoeven1 and Judith R. Kroep1*
Abstract
Growing preclinical evidence shows that short-term fasting (STF) protects from toxicity while enhancing the efficacy of
a variety of chemotherapeutic agents in the treatment of various tumour types. STF reinforces stress resistance of
healthy cells, while tumor cells become even more sensitive to toxins, perhaps through shortage of nutrients to satisfy
their needs in the context of high proliferation rates and/or loss of flexibility to respond to extreme circumstances. In
humans, STF may be a feasible approach to enhance the efficacy and tolerability of chemotherapy. Clinical research
evaluating the potential of STF is in its infancy. This review focuses on the molecular background, current knowledge
and clinical trials evaluating the effects of STF in cancer treatment. Preliminary data show that STF is safe, but
challenging in cancer patients receiving chemotherapy. Ongoing clinical trials need to unravel if STF can also diminish
toxicity and increase efficacy of chemotherapeutic regimes in daily practice.
Keywords: Short-term fasting, Fasting-mimicking diet, Chemotherapy, Differential stress resistance, Differential stress
sensitization, Toxicity
Background
Chronic caloric restriction reduces and delays cancer inci-
dence, and inhibits tumor progression and metastasis in ro-
dents [1–5]. Accordingly, cancer incidence and mortality are
strongly reduced in chronic calorie restricted non-human
primates [6]. Studies of long-term calorie restricted human
subjects have shown a reduction of metabolic and hormonal
factors associated with cancer risk [7–9]. However, chronic
caloric restriction is not a feasible clinical intervention.
Evident difficulties, such as the long period required to be ef-
fective, and unacceptable weight loss [10, 11], hamper clinical
application in cancer patients.
Preclinical studies suggest that short-term fasting (STF)
protects rodents from toxic effects of chemotherapy, while
simultaneously enhances the efficacy of a variety of che-
motherapeutic agents in numerous distinct malignancies,
e.g. breast cancer, melanoma, neuroblastoma, pancreatic
cancer, and colorectal cancer [12]. In distinct strains of
mice bearing xenograft malignancies, tumor growth
clearly slows down in response to chemotherapy com-
bined with a 24–60 h fast as compared to treatment with
chemotherapy alone [13–17]. STF simultaneously protects
mice from chemotoxicity as well, because it reinforces
stress resistance of healthy cells [17–24]. The distinct re-
sponse of healthy versus tumor cells to STF is called dif-
ferential stress resistance (DSR). During nutrient
deprivation, healthy cells re-invest energy in maintenance
and repair that contribute to resistance to chemotherapy,
while tumor cells are unable to slow down growth due to
mutations in tumor suppressor genes and mitogenic path-
ways [19, 25]. Moreover, low serum levels of glucose dur-
ing STF impose extra stress on tumor cells, as their
energy needs under these circumstances are primarily met
by means of glycolysis [14]. As a consequence of these dif-
ferential responses of healthy versus cancer cells to STF,
chemotherapy causes more DNA damage and apoptosis
in tumor cells, while leaving healthy cells unharmed when
it is combined with STF. Thus, STF protects healthy cells
against the toxic properties of chemotherapy and renders
tumor cells more sensitive, a phenomenon called differen-
tial stress sensitization (DSS).
In contrast to most cancer therapies, STF has only
mild side effects, such as headaches, dizziness, nausea,
weakness and short-term weight loss in humans [26].
Therefore, STF is a promising strategy to enhance the
efficacy and tolerability of chemotherapy in cancer
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patients, especially as STF is an affordable and accessible
approach and is potentially effective in a wide variety of
tumors [12]. However, patients with severe weight loss,
sarcopenia, cachexia or malnutrition are probably not
good candidates for a STF intervention [27, 28]. Recent
guidelines recommend to increase protein and fat con-
sumption in patients with cachexia [29, 30]. Thus, STF
may be particularly useful for relatively fit patients
treated with (neo)adjuvant chemotherapy.
This narrative review will cover the current knowledge
of the molecular mechanisms explaining “differential
stress resistance” of healthy- and cancer cells in response
to STF. Moreover, it summarizes the available clinical
data reflecting the impact of STF on the effects of
chemotherapy in cancer patients. Finally, ongoing clin-
ical studies of the effects of STF in cancer treatment will
be critically reviewed.
Differential stress resistance and sensitization in
response to STF
In healthy cells, nutrient deprivation shuts down path-
ways promoting growth to re-invest energy in mainten-
ance and repair pathways (Fig. 1) [25, 31, 32]. This
results in increased cellular protection, contributing to
enhanced resistance to distinct stressors including
chemotherapy and radiotherapy [19, 33]. In contrast,
tumor cells are unable to activate this protective re-
sponse, due to: 1) uncontrolled activation of growth
pathways and self-sufficiency in growth signals caused
by oncogenic mutations or autocrine production of
growth factors, and 2) loss of anti-proliferative signals
due to mutations in tumor suppressor genes [34]. Thus,
acquiring the ability to increase growth, tumor cells lose
the ability to adapt to extreme environments, including
nutrient deprivation. Additionally, the persistent in-
creased growth rate of tumor cells requires abundant
nutrients [35]. Therefore, STF increases DSS of tumor
cells to several chemotherapeutic agents, radiotherapy
and tyrosine kinase inhibitors (TKIs) (Table 1) [12–16,
18–20, 36–40]. Although the exact mechanism of DSR
and DSS by STF is unknown, several growth factors and
nutrient sensing pathways have been proposed to be key
regulators, of which insulin-like growth factor-1 (IGF-1)
is the most examined [41–43]. Nutrient sensing path-
ways are activated or inhibited in response to a low
amount of available nutrients and are highly con-
served among distinct organisms to overcome periods
of famine [44]. During nutrient scarcity, these path-
ways guide cells to invest energy in repair and main-
tenance rather than reproduction and growth [45–47],
presumably to enhance survival of periods of famine.
Analogously, infection-induced anorexia is a common
sign of sickness and may be an important strategy for
host defence [48, 49].
IGF-1 and insulin as key regulators of DSR
IGF-1 and insulin stimulate proliferation and growth
and inhibit apoptosis in response to calorie and protein
availability through signalling via the IGF-1 receptor
(IGF-1R) and insulin receptor isoform A (IR-A), respect-
ively [50–53]. Serum IGF-1 levels decrease during STF
[54–56], because low insulin levels cause growth hor-
mone (GH) resistance of the liver, which inhibits hepatic
IGF-1 production [54, 57, 58]. Both insulin and IGF-1
activate the Ras/mitogen-activated protein kinase
(MAPK) and phosphatidylinositol-3-kinase (PI3K)/Akt
pathways. In healthy cells, inhibition of proliferation
and/or investment in maintenance may contribute to in-
creased stress resistance. For example, mice with a liver
Igf1 gene deletion (LID), which have decreased IGF-1
levels similar to those during STF [59–61], exhibit in-
creased resistance to high doses of various chemothera-
peutic agents [42] and this benefit was nullified through
IGF-1 administration [12, 42]. Thus, the IGF-1R path-
way seems to be a key mediator of stress resistance in
response to STF in healthy cells.
During STF, the Ras/MAPK and PI3K/Akt pathways
are down-regulated in cancer cells, whereby proliferation
Fig. 1 Schematic overview of differential effects of short-term
fasting on healthy and cancer cells. Abbreviations: STF; short
term fasting, IGF-1: insulin growth factor-1.
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is inhibited [64]. Notably, resistance to the growth limit-
ing effects of STF has been observed in cancer cells car-
rying mutations that cause a constitutive activation of
the PI3K pathway, since these cells proliferate even in
the absence of insulin or IGF-1 [65]. Therefore, the
IGF-1R pathway is a key mediator of cancer cell growth
and cancer resistance to commonly used therapeutics
[42, 66, 67]. Thus, the reduction in circulating levels of
IGF-1 and insulin during STF may contribute to the an-
ticancer activity as well [68].
AMPK and autophagy
AMP-activated protein kinase (AMPK) may play a
major part in DSR due to STF [69]. AMPK monitors
cellular energy levels and becomes activated when
ADP:ATP or AMP:ATP ratios in the cell increase
[70]. AMPK inhibits energy consuming processes,
such as cell proliferation and protein synthesis, and
activates energy generating processes, such as glycoly-
sis and fatty acid oxidation. It inhibits cell growth
and stimulates autophagy [71]. Autophagy (Greek for
“self-eating”) is a highly conserved catabolic process
among eukaryotes to survive periods of nutrient
deprivation. This adaptive response of the cell in-
volves damaged protein and organelle degradation to
generate amino acids as an alternative energy source
[72, 73]. Activation of AMPK and autophagy seems to
play a major part in de protective effects of STF in
healthy cells [17].
However, the effects of AMPK activation in distinct
tumor cells may vary, as some tumors harbour constitu-
tively active AMPK [74, 75] and others exhibit low
AMPK activity [76–78]. Tumors with diminished AMPK
activity or autophagy may be highly sensitive to STF, as
AMPK activation enhances immune surveillance [40],
whereas tumors with highly active AMPK or autophagy
may be resistant [77, 79–82].
Glucose metabolism and the “Warburg effect”
During STF, healthy cells, have the metabolic flexibility
to cope with nutrient deprivation, since glucose can be
replaced by ketone bodies and fatty acids as primary en-
ergy source.
In contrast, tumor cells depend on glucose to maintain
the high rate of cellular proliferation [83, 84]. Akt
stimulates the so called “Warburg effect”, characterized by
an increased rate of glycolysis rather than oxidative phos-
phorylation even in the presence of oxygen [83–85]. STF
down-regulates anaerobic glycolysis while up-regulating
oxidative phosphorylation in tumor cells, and this “anti--
Warburg effect” results in oxidative stress and apoptosis
[14]. Also, a counterintuitive increase in protein translation
during STF increases unmet energy needs, leading to cell
death [12]. Moreover, the 20–40% reduction in circulating
glucose during STF may be enough to kill anoxic tumor
cells [85]. Thus, a decrease in nutrient availability during
STF makes cancer cells more vulnerable to any challenge,
including chemotherapy. However, overconsumption after
a STF period might accelerate tumor growth, due to high
glucose conditions and increased glycolysis [86].
Reactive oxygen species and DNA damage
Chemotherapeutic agents inflict oxidative stress and
DNA damage upon healthy cells, which are underlying
mechanisms of toxicity [44, 87]. STF dampens oxidative
stress in healthy cells by down-regulating metabolic rate
and increasing scavenging of reactive oxygen species
(ROS), which may contribute to DSR [33, 44]. As serum
glucose levels decrease during STF, fatty acids serve as
the main energy source. Beta-oxidation of fatty acids
produces ketone bodies, which can be used as an alter-
native/additional fuel. Ketone bodies can also activate
pathways involved in protection against ROS [88]. More-
over, STF presumably activates DNA repair processes in
healthy cells [22]. For example, in mice fasted for 24 h
before high dose infusion of etoposide, less DNA dam-
age was seen in small intestinal stem cells 3 h after the
infusion compared to mice who ate ad libitum. As 1.5 h
post-treatment DNA damage was similar, DNA repair
was likely more efficient in healthy cells due to STF [21].
In contrast, tumor cells exhibit increased ROS produc-
tion if chemotherapy is combined with STF in vitro [12].
In breast cancer cells cultured in low glucose medium or
serum of fasting mice, a 20-fold increase in DNA dam-
age was seen in response to chemotherapy, as compared
to cells cultured in regular medium or in serum of ad
libitum fed mice [12].
Immune competence
Chemotherapy causes bone marrow toxicity and deple-
tion of circulating immune cells, especially myeloid cell
depletion [89, 90]. Fasting protects hematopoietic stem
cells and circulating immune cells from the detrimental
effects of chemotherapy in mice [22, 91]. Additionally,
more efficient immunity as a result of STF presumably
causes a lower rate of infections and febrile neutropenia
as well [92].
On the other hand, fasting improves the therapeutic ef-
fect of chemotherapy on the tumor possibly through cellu-
lar immunity in mice, as this effect is nullified in nu/nu
mice, which lack T cells [40, 93]. Thus, STF may promote
immunity and presentation of tumor-associated antigens
(TAA), which promote efficient antitumor immunity con-
tributing to increased efficacy of chemotherapy [94].
From animal models to the clinic
Preclinical data documenting the benefits of STF is
abundant and promising. However, words of caution are
de Groot et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:209 Page 5 of 14
appropriate regarding its application in patients with
cancer. For instance, preclinical studies show severe, al-
beit transient, weight loss in animal models (20–40% of
total bodyweight after 24–48 h of fasting [12, 19, 23, 39,
95]. In contrast, the impact of a few days of fasting on
bodyweight of humans appears far more modest (~ 1 kg
per day, largely water loss) [26], which is probably ex-
plained by metabolic differences between humans and
mice [95]. This is reassuring in the context of safety.
However, it may also mean that humans need to fast for
a (much) longer period of time than mice to obtain the
same benefits (see discussion below). Therefore, carefully
controlled clinical trials monitoring tumor growth as
well as adverse effects of distinct dietary regimes are re-
quired before fasting mimicking diets (FMDs) can be ap-
plied in clinical practice.
Metabolic risk factors for cancer
Obesity is associated with an increased risk of develop-
ing several cancers, such as breast cancer, colon cancer,
ovarian cancer, endometrial cancer and thyroid cancer
[96, 97] and IGF-1 levels are positively associated with
the risk of developing breast and prostate cancer [98,
99]. Moreover, obesity and high levels of insulin and
IGF-1, as well as having diabetes mellitus are associated
with worse survival in cancer [100–103]. Obese subjects
are often hyperglycemic and hyperinsulinemic, as a re-
sult of insulin resistance. Although circulating levels of
total (free + bound) IGF-1 are normal or even low in
obese subjects, levels of free (bioactive) IGF-1 are higher
than in lean subjects [104]. Both insulin and free IGF-1
can bind the IGF-1R and IR-A [105] and activate the
Ras/MAPK and PI3K/AKT pathway, through which cell
proliferation is stimulated and apoptosis is inhibited, re-
spectively [106]. Moreover, preclinically, obesity is asso-
ciated with macrophage accumulation in adipose tissue
resulting in an immune suppressive microenvironment
[107]. These metabolic mechanisms may explain the in-
creased risk of cancer as well as the worse prognosis of
several cancers in obese subjects.
Clinical studies of fasting
Voluntary fasting has been performed for many centur-
ies and purposes, such as religious, ethical and cosmetic
[26, 108]. Hippocrates was probably one of the first ad-
vocates of fasting for medical purposes (he recom-
mended to fast during sickness). Since then, several
doctors advised their patients to listen to their ‘fasting
instinct’ (the natural loss of appetite during disease).
Scientific research on the biomedical effects of fasting
was performed from the late nineteenth century on,
when several non-obese humans fasted for 20–40 days
[26]. The first clinical study of medical fasting for the
treatment of obesity was performed in 1915 [109]. The
authors reported that short periods of four to six days of
fasting is a safe and effective method for reducing body-
weight in obese humans. Since that time several studies
were performed in obese subjects, with the longest fast-
ing period lasting 382 days (!) [110, 111]. Fasting therapy
was observed to be generally safe and well tolerated.
Only mild side effects were reported, including
headaches, dizziness, nausea, dyspepsia and fatigue
[109–114]. However, in rare cases fasting for periods
longer than 2 weeks was fatal in obese subjects with co-
morbidities as cardiac disease or diabetes mellitus [26,
115–117], and in one rare case a 53-day fast caused
Wernicke encephalopathy in a patient with a lymphoma
[118]. Additionally, fasting is not suitable for patients
with rare metabolic illnesses such as glycogen storage
disease or disorders of gluconeogenesis [119]. Benefits of
fasting are improved cardiovascular risk factors, such as
a decrease in blood pressure, improvement of lipid pro-
file and insulin sensitivity, and weight loss in obese and
non-obese subjects [114, 120]. The weight loss during
STF is approximately 0.9 kg per day and decreases dur-
ing prolonged fasting to 0.3 kg per day by the third week
[26, 121]. Various studies examined the potential of fast-
ing in the treatment of mood disorders, rheumatic dis-
eases, asthma, chronic pain syndromes, hypertension,
and metabolic syndrome [122, 123]. For example, a large
cohort study of more than 2000 subjects with chronic
illness and pain syndromes, who used a very low-calorie
diet of 350 kcal per day for 7 days, showed an increase in
quality of life without any serious side effect [122]. In
healthy subjects, STF by 3 cycles of a fasting mimicking
diet (FMD) reduces common risk factors for cardiovas-
cular diseases, diabetes and ageing, such as lowering
blood pressure, body weight, glucose, triglycerides and
cholesterol [124]. Additionally, STF may improve clinical
outcome in patients undergoing a partial liver resection
and may prevent acute kidney injury after cardiac sur-
gery [125, 126].
Metabolic changes during STF in humans
STF has profound metabolic effects in humans [127].
Serum glucose levels drop after a few hours and are
maintained at a lower level by endogenous glucose pro-
duction, stimulated by glucagon. Glycogen storage cap-
acity is limited so that stores are virtually depleted after
24 h. From then on, gluconeogenesis provides the brain
with glucose as its major fuel source. Fatty acids are the
primary fuel for the rest of the body. Beta-oxidation of
fatty acids produces ketone bodies, which can serve as
auxiliary energy source for the brain and the rest of the
body. Insulin levels decrease rapidly and IGF-1 decreases
dramatically after 36–72 h [41]. Since the liver is resist-
ant to GH during prolonged fasting, IGF-1 production is
profoundly reduced [128]. Diminished negative feedback
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control through reduction of circulating insulin and
IGF-1 causes plasma GH levels to increase [129, 130].
IGF binding proteins, which regulate the bio-availability
of IGF-1, change during fasting as well [41, 131, 132].
IGF-BP3 levels decrease, while IGF-BP1 levels increase
5–10-fold [133]. The decrease of IGF-I, downregulates
the Ras/MAPK and PI3K/Akt pathways, through which
cell proliferation is stimulated and apoptosis inhibited
[12, 19]. Moreover, fasting down-regulates the
hypothalamus-pituitary-thyroid axis activity. It particu-
larly lowers triiodothyronine (T3), while thyroid stimu-
lating hormone (TSH) and free thyroxine (fT4) are
slightly decreased or not affected [134]. Clinical research
shows that fasting periods longer than 48 h are required
to facilitate a robust decrease in IGF-1 levels [41].
Therefore, it is likely that the positive effects of STF will
be enhanced if the period of fasting is prolonged. A low
sugar, low protein FMD may be an alternative to ease
the burden of fasting, as it mimics the effects of STF on
metabolism [91].
Clinical studies of STF during chemotherapy
To date, a few small clinical studies in humans exploring
the effects of STF combined with chemotherapy have
been published (Table 2) [22, 131, 135–138]. The design
and results of these studies in humans are summarized
below.
In a case series from the University of Southern Cali-
fornia (USC), 10 patients with distinct malignancies
fasted in combination with docetaxel, carboplatin, pacli-
taxel and/or gemcitabine [136, 139]. Seven female and
three male patients, with a median age of 61 years, diag-
nosed with breast (N= 4), prostate (N = 2), esophagus,
non-small cell lung cancer, uterus and ovary cancer were
described. Patients fasted for 48–140 h prior to, and 5–
56 after commencing chemotherapy. Six of the ten
patients fasted alternately during the chemotherapy cy-
cles (the other four fasted every cycle) and side effects
were compared between cycles combined with STF and
chemotherapy alone. Side effects were scored according
to the Common Terminology Criteria for Adverse
Events (CTCAE) 4.0. Besides hunger and dizziness, fast-
ing had no significant side effects. The authors reported
a decrease in chemotherapy-induced side effects, includ-
ing fatigue, weakness, vomiting and diarrhea, when
chemotherapy was combined with STF compared to
chemotherapy alone. In five patients the tumor volume
(evaluated with PET or PET-CT) or tumor markers
(PSA or CA-125) were evaluated. STF did not diminish
chemotherapy-induced reduction of tumor volume and
tumor markers, suggesting that STF did not interfere
with the efficacy of chemotherapy.
In the King Fahad Medical City a clinical trial
(NCT00757094) was conducted to evaluate the safety and
feasibility of combining chemotherapy and intermittent
fasting (including liquids) during the Ramadan [135].
Eleven patients, with distinct types of malignancies, re-
ceived one gift of chemotherapy. Side effects and blood
counts were compared with values measured in response
to a similar dose of chemotherapy, given 2 weeks after the
end of Ramadan. The authors concluded that combining
fasting and chemotherapy during the month of Ramadan
was well tolerated and safe. Side effects of chemotherapy
tended to be less. However, because the study group was
small, no statistics were performed. Moreover, due to the
short fasting period (approximately 12 h), major benefits
may not be expected, as IGF-1 levels will evidently not be
reduced [140].
We performed a randomized pilot study (NCT01304251)
to evaluate the effects of short-term fasting on tolerance to
(neo) adjuvant chemotherapy in HER2-negative breast
cancer patients in the Leiden University Medical Cen-
ter (LUMC) [131]. Eligible patients had stage II/III
breast cancer and received (neo)-adjuvant TAC (doce-
taxel/doxorubicin/cyclophosphamide) chemotherapy.
Patients were randomized to fast 24 h before and 24 h
after chemotherapy, or to eat according to the guide-
lines for healthy nutrition. Metabolic parameters (glu-
cose, insulin and IGF-1) at baseline and immediately
before chemotherapy infusion –when patients in the
STF group had fasted for 24 h- were compared. Tox-
icity in the two groups was compared as well. Add-
itionally, chemotherapy-induced DNA damage was
quantified in peripheral blood mononuclear cells
(PBMCs) by the level of γ-H2AX, as determined by
flowcytometry. Thirteen patients were included, of
whom seven were randomized to the STF arm. STF
was well tolerated in our study. Plasma glucose levels
increased and insulin levels remained constant in re-
sponse to STF. We inferred that this phenomenon
was the result of the concomitant use of dexametha-
sone, which was administered as an anti-emetic, for
reduction of fluid retention and dampening of hyper-
sensitivity reactions in response to docetaxel. Circulat-
ing IGF-1 levels were only modestly reduced in the
study, which could be due to the use of dexametha-
sone as well [141, 142] or to the relatively short dur-
ation (24 h) of fasting prior to chemotherapy.
Non-hematological toxicity did not differ between the
groups. However, mean erythrocyte- and thrombocyte
counts 7 days post-chemotherapy were significantly
higher in the STF group compared to the non-STF
group. Levels of γ-H2AX were significantly increased
30 min post-chemotherapy in CD45 + CD3- cells in
non-STF, but not in STF patients [131]. This study
provides evidence that STF attenuates bone marrow
toxicity in these patients and reduces chemotherapy-induced
DNA damage in PBMCs and/or accelerates its recovery.
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Moreover, Dorff et al. reported results from a
dose-escalating phase I study (NCT00936364),
wherein 20 human subjects with distinct malignancies
were treated with platinum-based chemotherapy com-
bined with 24, 48 or 72 h STF to identify the optimal
fasting duration [22, 137]. Eligible patients had dis-
tinct cancer types for which platinum-based combin-
ation chemotherapy was given with curative or
palliative intent. Metabolic parameters (glucose, insu-
lin, IGF-1 and IGF-BP1) at baseline and immediately
before chemotherapy were compared. Moreover, tox-
icities and chemotherapy-induced DNA damage in
PBMCs (determined by the COMET assay) between
the three groups were compared. Twenty patients
were included, 6 in the 24 h group and 7 in the 48
and 72 h group. The fasting was feasible and
fasting-related toxicities were limited to grade 1 ac-
cording CTCAE 4.0. The authors reported that 72 h
of STF was associated with normal lymphocyte counts
and maintenance of a normal lineage balance in white
blood counts (lymphoid/myeloid ratio) after 2 cycles
of chemotherapy, while 24 h STF was not [22]. IGF-1
levels decreased by 30, 33 and 8% in the 24, 48 and
72 h fasting cohorts, respectively, after the first fasting
period. Additionally, the COMET assay showed re-
duced DNA damage 24 h after chemotherapy in leu-
kocytes from subjects who fasted for more than 48 h
compared with subjects fasted for 24 h (P = 0.08).
Finally, Bauerfeld et al. published a randomized
cross-over trial (NCT01954836) evaluating the effect
of STF on quality of life in breast cancer and ovarian
cancer patients treated with chemotherapy [138]. Pa-
tients were randomized to fast, using an FMD, 36 h
before and 24 h after chemotherapy or to eat a nor-
mocaloric Mediterranean diet for the first three cycles
of chemotherapy. After three cycles the patient
crossed over to the other group of nutrition (Mediter-
ranean diet or fasting). The design of the study allows
intra-individual comparisons regarding side effects of
treatment, but precludes conclusions as efficacy of
chemotherapy. In total, 50 patients were included in
the study, but only 34 were analyzed because of early
study discontinuation. The fasting was safe and feas-
ible and five patients (14.7%) continued fasting after
three cycles and did not cross over to the normocalo-
ric diet. The authors concluded that STF led to a bet-
ter tolerance to chemotherapy with less compromised
quality of life (QOL) and reduced fatigue within the
8 days after chemotherapy. Moreover, 31 patients de-
clared that they would fast again during chemother-
apy, while only 3 patients declared that they would
not fast again during chemotherapy.
These first clinical studies lack enough power to draw
definite conclusions. However, the first results suggest that
STF is safe, while it reduces toxicity of chemotherapy.
Large scale randomized studies are required to get more
insight in the benefits of STF in cancer treatment in
humans.
Ongoing studies
The first clinical studies have shown that STF com-
bined with chemotherapy is safe and feasible in small
patient groups [131, 136, 138]. Moreover, STF may
reduce chemotherapy-induced toxicity. Additionally,
chemotherapy-induced DNA damage in healthy cells
may be decreased due to STF. However, large ran-
domized clinical studies are required to generate
(more) insight and validate the possible benefits of
STF during chemotherapy. In Table 3, an overview is
shown of the ongoing trials with STF combined with
cancer treatment.
One study to date investigates the effects of STF on
the effects radiotherapy. This randomized study
(NCT01754350) conducted in Johann Wolfgang Goethe
University Hospitals, includes patients with recurrent
glioblastoma or gliosarcoma. The intervention entails 3
days of STF and 6 days of ketogenic diet during
re-irradiation. The primary endpoint of the study is pro-
gression free survival.
A phase II study (NCT01802346), ongoing in the Uni-
versity of Southern California, examines the effects of an
FMD on toxicity of chemotherapy in patients with breast
and prostate cancer.
The phase II/III study (NCT02126449) from the LUMC,
investigates the effects of STF using an FMD on toxicity
(phase II part) and efficacy (phase III part) of neo-adjuvant
AC-T or FEC-T chemotherapy. In this study prophylactic
dexamethasone is omitted in the FMD arm during the AC
and FEC chemotherapy cycles to reduce its potentially
counteractive metabolic effects. Final results of the study
are awaited [68]. The same FMD will be used to investigate
the effect on circulating tumor cells in non-small cell lung
cancer during treatment with carboplatin, pemetrexed and
pembrolizumab.
Another FMD, described by Bauerfeld [138], is tested in
two studies (NCT02710721, NCT03162289) conducted in
the Charité University in Berlin, one in advanced meta-
static prostate cancer and another in ovarian or breast
cancer. Primary endpoint of both studies is QOL.
Finally, three studies (NCT03340935, NCT03595540
and NCT03709147) investigate the feasibility and effect
of a 5-day FMD (approximately 700 kcal a day) on
chemotherapy in distinct tumors and distinct chemo-
therapy regimens.
Discussion and clinical implications
Clinical research evaluating the potential of STF is still in
its infancy and more research is needed as the exact
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mechanism and effects are not established yet. Remaining
questions are: is STF clinically effective in patients with
solid tumors, in which tumors is STF effective, which
markers are useful for prediction and monitoring of effi-
cacy, what is the optimal length and timing of STF and
refeeding, is STF safe in all patients, what is the optimal
composition of an FMD, how can we increase patient’s
compliance?
STF may be an affordable and safe intervention - at
least in patients without severe weight loss or malnu-
trition -, which potentially dampens the side effects
of chemotherapy, radiotherapy and TKI’s, while re-
inforcing their efficacy. Furthermore, it is potentially
effective in a wide variety of tumors, although there
is evidence that tumors with PI3K mutations or
highly active AMPK are not sensitive [65, 82]. Reduc-
tion of side effects would improve quality of life and
potentially reduce costs of hospitalization and the use
of drugs such as anti-emetics or antibiotics. Moreover,
STF may broaden the therapeutic window of cancer
treatments, allowing for an increase of the dosage of
(chemo) therapeutic agents, thereby enhancing their
efficacy. However, STF might be only feasible in che-
motherapeutic regimens characterized by: 1) bolus in-
fusions on one day, to keep the fasting period short,
2) a long interval between two cycles, to ensure suffi-
cient recovery time between cycles and 3) low dose
or no use of corticosteroids, to avoid hyperglycemia,
which might interfere with the benefits of STF [131].
Patients at risk for malnutrition or cachexia may not
be candidates for STF, as it may be unsafe to further
limit nutrient intake in these patients for even a short
time [27]. However, notably, in preclinical setting caloric
restriction showed even preservation of muscle strength
in cancer cachexia [143]. Therefore, robust clinical trials
are needed to establish the safety and efficacy of FMD in
patients at high risk of cachexia.
Close monitoring of patients by nutritionists with ex-
pertise in fasting may be needed to increase compliance
in future studies and to prevent patients unacceptable
weight loss. Moreover, in our opinion, STF or FMDs
should only be applied in the context of clinical research
in patients with cancer until there is robust evidence for
their safety and benefits.
Conclusion
Abundant and convincing preclinical evidence shows
that STF can decrease toxicity and simultaneously in-
crease efficacy of a wide variety of chemotherapeutic
agents. Preclinical data suggesting that STF can en-
hance the effects of radiotherapy and TKIs are prom-
ising as well. In clinical studies, STF emerges as a
promising strategy to enhance the efficacy and toler-
ability of chemotherapy. It appears safe as an adjunct
to chemotherapy in humans, and it may reduce side
effects and DNA damage in healthy cells in response
to chemotherapy. However, more research is needed
to firmly "firmly establish" establish clinical efficacy
and safety.
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